Preliminary study of bone marrow-derived mesenchymal stem cells pretreatment with erythropoietin in preventing acute rejection after rat renal transplantation

Renal transplantation is currently the most effective treatment for end-stage kidney diseases, and acute allograft rejection is well treated with high dose prednisolone and immunosuppressive agent, but long-term use of immunosuppressants will be detrimental to the long-term survival of the transplanted kidney and will have a lot of side effects on the human body. Thus, a local and alloantigen-specific immunological tolerance may be a promising approach to improve kidney transplantation. The aim of this study is to examine the therapeutic potential of transforming bone marrow-derived mesenchymal stem cells (BMSCs) pretreated with erythropoietin (EPO) in inducing immunosuppression in renal grafts after transplantation.

Source: Transplantation Proceedings - May 3, 2018 Category: Transplant Surgery Authors: Y. Zhang, S. Zhou, J.M. Hu, H. Chen, D. Liu, M. Li, Y. Guo, L.P. Fan, L.Y. Li, Y.G. Liu, M. Zhao Source Type: research